155 related articles for article (PubMed ID: 22182499)
21. Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series.
Oubrie A; Kaptein A; de Zwart E; Hoogenboom N; Goorden R; van de Kar B; van Hoek M; de Kimpe V; van der Heijden R; Borsboom J; Kazemier B; de Roos J; Scheffers M; Lommerse J; Schultz-Fademrecht C; Barf T
Bioorg Med Chem Lett; 2012 Jan; 22(1):613-8. PubMed ID: 22119462
[TBL] [Abstract][Full Text] [Related]
22. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.
Venkatesan AM; Dehnhardt CM; Chen Z; Santos ED; Dos Santos O; Bursavich M; Gilbert AM; Ellingboe JW; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham R; Mansour TS
Bioorg Med Chem Lett; 2010 Jan; 20(2):653-6. PubMed ID: 19954970
[TBL] [Abstract][Full Text] [Related]
23. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
[TBL] [Abstract][Full Text] [Related]
24. Theoretical analysis of the binding of potential inhibitors to protein kinases MK2 and MK3.
Araújo PM; da Silva LP; Esteves da Silva JC
Med Chem; 2015; 11(6):573-9. PubMed ID: 25665652
[TBL] [Abstract][Full Text] [Related]
25. Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects.
Constantine KL; Mueller L; Metzler WJ; McDonnell PA; Todderud G; Goldfarb V; Fan Y; Newitt JA; Kiefer SE; Gao M; Tortolani D; Vaccaro W; Tokarski J
J Med Chem; 2008 Oct; 51(19):6225-9. PubMed ID: 18771253
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of dibenz[b,f][1,5]oxazocine derivatives for agonist activity at κ-opioid receptor.
Mitra S; Banerjee TS; Hota SK; Bhattacharya D; Das S; Chattopadhyay P
Eur J Med Chem; 2011 May; 46(5):1713-20. PubMed ID: 21392859
[TBL] [Abstract][Full Text] [Related]
27. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
Miglani R; Cliffe IA; Voleti SR
Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
[TBL] [Abstract][Full Text] [Related]
28. Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.
Abraham S; Hadd MJ; Tran L; Vickers T; Sindac J; Milanov ZV; Holladay MW; Bhagwat SS; Hua H; Ford Pulido JM; Cramer MD; Gitnick D; James J; Dao A; Belli B; Armstrong RC; Treiber DK; Liu G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5296-300. PubMed ID: 21802948
[TBL] [Abstract][Full Text] [Related]
29. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
[TBL] [Abstract][Full Text] [Related]
30. [Synthesis of derivatives of perhydroazepine, perhydro-1,5-oxazocine, morpholine and piperazine containing 3-(isopropylamino)-propan-2-ol group--compounds with potential effect on the circulatory system and central nervous system].
Kotełko B; Mikołajewska H; Glinka R; Guryn R
Acta Pol Pharm; 1985; 42(5):433-6. PubMed ID: 3834763
[No Abstract] [Full Text] [Related]
31. Low-molecular-weight MK2 inhibitors: a tough nut to crack!
Schlapbach A; Huppertz C
Future Med Chem; 2009 Oct; 1(7):1243-57. PubMed ID: 21426101
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
[TBL] [Abstract][Full Text] [Related]
33. Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.
Schlapbach A; Feifel R; Hawtin S; Heng R; Koch G; Moebitz H; Revesz L; Scheufler C; Velcicky J; Waelchli R; Huppertz C
Bioorg Med Chem Lett; 2008 Dec; 18(23):6142-6. PubMed ID: 18945615
[TBL] [Abstract][Full Text] [Related]
34. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
35. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Tsou HR; MacEwan G; Birnberg G; Zhang N; Brooijmans N; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K
Bioorg Med Chem Lett; 2010 Apr; 20(7):2259-63. PubMed ID: 20188551
[TBL] [Abstract][Full Text] [Related]
36. Structural analysis of carboline derivatives as inhibitors of MAPKAP K2 using 3D QSAR and docking studies.
Nayana RS; Bommisetty SK; Singh K; Bairy SK; Nunna S; Pramod A; Muttineni R
J Chem Inf Model; 2009 Jan; 49(1):53-67. PubMed ID: 19119997
[TBL] [Abstract][Full Text] [Related]
37. Novel 1-(2-aminopyrazin-3-yl)methyl-2-thioureas as potent inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
Lin S; Lombardo M; Malkani S; Hale JJ; Mills SG; Chapman K; Thompson JE; Zhang WX; Wang R; Cubbon RM; O'Neill EA; Luell S; Carballo-Jane E; Yang L
Bioorg Med Chem Lett; 2009 Jun; 19(12):3238-42. PubMed ID: 19423344
[TBL] [Abstract][Full Text] [Related]
38. Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials.
Fiore M; Forli S; Manetti F
J Med Chem; 2016 Apr; 59(8):3609-34. PubMed ID: 26502061
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors.
Kawakita Y; Seto M; Ohashi T; Tamura T; Yusa T; Miki H; Iwata H; Kamiguchi H; Tanaka T; Sogabe S; Ohta Y; Ishikawa T
Bioorg Med Chem; 2013 Apr; 21(8):2250-2261. PubMed ID: 23490150
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and characterization of "clickable" 4-anilinoquinazoline kinase inhibitors.
Perera BG; Maly DJ
Mol Biosyst; 2008 Jun; 4(6):542-50. PubMed ID: 18493651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]